window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : March 16, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

biotech funding Europe

  • Central Nervous System,Clinical Development,Clinical Trials,Funding

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    February 16, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  •
    ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen
    Categories: Clinical Development, Infectious Diseases, Patient Centricity, Precision medicine
  • SPT Labtech and Illumina to develop automated platform for decentralised oncology genomics
    Categories: Diagnostics, Oncology, Partnerships & Funding
  • Young adults in US, UK and Australia hit hardest by global mental health decline
    Categories: Clinical studies, Digital Health, Global health, Mental health, Neurosciences
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top